A positive influence of GLP-1 (gut-derived glucagon-like peptide-1) receptor agonists, which are approved for the treatment of type 2 diabetes mellitus, was suggested (Lee and Jun, 2016; Nauck et al., 2021). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.